Drugs / BCMA/CD19 CAR T cells
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04795882 | Apr 2022 → Mar 2029 expected | plasma cell myeloma | University College, London | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BCMA/CD19 CAR T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04795882 ↗ |
| Modality | Cell therapy | “CAR T cells engineered to co-express BCMA CAR and a CD19 CAR” NCT04795882 ↗ |
| Route | Other | “Infusion with ATIMP: BCMA/CD19 CAR T-cells” NCT04795882 ↗ |